Tianjin Biolight Meditech Co., Ltd. announced that it expects to receive CNY 60 million in funding from Guangdong Biolight Meditech Co., Ltd.
November 05, 2020
Share
Tianjin Biolight Meditech Co., Ltd. announced that it will receive CNY 60,000,000 in equity funding from existing investor Guangdong Biolight Meditech Co., Ltd. (SZSE:300246) on November 6, 2020. The investor continues to own 100% stake in the company. The registered capital will increase from CNY 30,000,000 to CNY 90,000,000. The transaction has been approved in the 11th meeting of the 7th directorate and the 11th meeting of the 7th supervisory board of the investor, and does not need its shareholders’ approval.
GUANGDONG BIOLIGHT MEDITECH CO., LTD. is a China-based company principally engaged in the research, development, production and sales of medical monitoring equipment, hemodialysis products and ancillary products. Its medical monitoring equipment includes monitoring equipment, electrocardiograph, pulse oximeters and central monitoring systems. Its hemodialysis products include hemodialysis machines, hemodialyzers, hemodialysis powders/dialysates and perfusion machines. The Company distributes its products in domestic and overseas markets.
GUANGDONG BIOLIGHT MEDITECH CO., LTD. 
